SV2002000761A - Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv - Google Patents

Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv

Info

Publication number
SV2002000761A
SV2002000761A SV2001000761A SV2001000761A SV2002000761A SV 2002000761 A SV2002000761 A SV 2002000761A SV 2001000761 A SV2001000761 A SV 2001000761A SV 2001000761 A SV2001000761 A SV 2001000761A SV 2002000761 A SV2002000761 A SV 2002000761A
Authority
SV
El Salvador
Prior art keywords
pirrolo
dihydroisoquinolins
ref
read
dihydroisoquinolines
Prior art date
Application number
SV2001000761A
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Niewohner
Marcus Bauser
Jens-Kerim Erguden
Dietmar Flubacher
Paul Naab
Thorsten-Oliver Repp
Juergen Stoltefuss
Buks Burkhardt
Andrea Sewing
Michael Schauer
Karl-Heinz Schlemmer
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2002000761A publication Critical patent/SV2002000761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SV2001000761A 2000-12-13 2001-12-12 Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv SV2002000761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25520600P 2000-12-13 2000-12-13
US31031201P 2001-08-06 2001-08-06

Publications (1)

Publication Number Publication Date
SV2002000761A true SV2002000761A (es) 2002-12-02

Family

ID=26944520

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000761A SV2002000761A (es) 2000-12-13 2001-12-12 Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv

Country Status (10)

Country Link
US (1) US6930114B2 (enExample)
EP (1) EP1347973A1 (enExample)
JP (1) JP2004517843A (enExample)
AU (1) AU2002227985A1 (enExample)
CA (1) CA2431326A1 (enExample)
HN (1) HN2001000277A (enExample)
PE (1) PE20021085A1 (enExample)
SV (1) SV2002000761A (enExample)
UY (1) UY27067A1 (enExample)
WO (1) WO2002048144A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236276A1 (en) * 2001-08-06 2003-12-25 Ulrich Niewohner Pyrrolo[2.1-a]isoquinoline derivatives
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
AU2003300883A1 (en) * 2002-12-12 2004-07-09 Cytovia, Inc. Substituted 1-benzoyl-3-cyano-pyrrolo(1,2-a)quinolines
WO2005003130A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
US20070105840A1 (en) * 2003-06-30 2007-05-10 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
WO2006089815A1 (en) * 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as pde10 inhibitors
US20080064714A1 (en) * 2005-01-12 2008-03-13 Nycomed Gmbh Novel Pyrrolodihydroisoquinolines
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
WO2008001182A1 (en) * 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5730896B2 (ja) * 2009-12-04 2015-06-10 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ トリシクロピラゾール誘導体
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (enExample) 1966-12-07 1967-05-16
FR7348M (enExample) * 1967-12-07 1969-10-13
US4719216A (en) 1983-06-23 1988-01-12 Mcneilab, Inc. Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants
DE3401018A1 (de) 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
GB8718980D0 (en) 1987-08-11 1987-09-16 May & Baker Ltd Compositions of matter
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
PE20021085A1 (es) 2003-05-16
US6930114B2 (en) 2005-08-16
JP2004517843A (ja) 2004-06-17
AU2002227985A1 (en) 2002-06-24
HN2001000277A (es) 2002-01-30
US20040138249A1 (en) 2004-07-15
UY27067A1 (es) 2002-07-31
EP1347973A1 (en) 2003-10-01
CA2431326A1 (en) 2002-06-20
WO2002048144A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
SV2002000761A (es) Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
HN2001000146A (es) Derivados de pirazol
PT1071665E (pt) Indolinonas substituidas com efeito inibidor sobre cinases e complexos de ciclina/cdk
ATE253576T1 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
GT200300005A (es) 2-(piridin-2-ilamino)-pirido[2,3-d] pirimidin-7-onas
AR028454A1 (es) Metodos para el ensamblaje enzimatico de polinucleotidos e identificacion de polinucleotidos que tienen caracteristicas deseadas
TR200001041T2 (tr) Opioid analjezik ve sayklooksijenaz-2 inhibitörünün sinerjistik analjezik kombinasyonu.
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
EE200300085A (et) Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
CY1119536T1 (el) Συνθεση μονομερων προστατευμενου 3'-αμινο νουκλεοζιδιου
CR9465A (es) Compuestos mejorados farmacocineticamente
DK1109812T3 (da) Pyrrolobenzodiazepiner
HN2003000227A (es) Inhibidores de quinasas
DK1150982T3 (da) Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
DE60106954D1 (de) Resorcin-derivate
BR9912327A (pt) Inibidores da uroquinase
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1108773T1 (el) 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση
ES2196559T3 (es) Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.